Pfizer and BioNTech’s updated bivalent booster retains protection against new omicron sublineages

[Image courtesy of Wikimedia Commons]

Pfizer (NYSE:PFE) and BioNTech (Nasdaq:BNTX) have announced that their omicron BA.4/BA.5-adapted bivalent booster fared well against novel omicron variants in neutralizing antibody detection tests.

The company published the results from the bivalent booster tests against the BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1 subvariants on the preprint server BioRxiv.

One month after administering a fourth vaccine dose, the geometric means of neutralization titers from the bivalent BA.4/5 vaccine was generally superior to that of the monovalent BNT162b2 booster. Overall, the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine was associated with a 3.2- to 4.8-fold increase in neutralizing antibody titers relative to the original monovalent Pfizer-BioNTech vaccine. For the BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1 omicron variants, antibody titers were up between 4.8- to 11.1-fold from pre…

Read more
  • 0

Biden urges Americans to get updated COVID-19 bivalent booster

Biden received the updated booster. [Image courtesy of the White House]

After receiving a COVID-19 bivalent booster on television, President Biden asked all eligible adults to receive their booster to help ward off a potential uptick in infections in the coming months. 

The updated vaccines from Pfizer/BioNTech (NYSE:/PFE, Nasdaq: BNTX) and Moderna (Nasdaq:MRNA) are “incredibly effective,” Biden said. “But the truth is, not enough people are getting [them].” 

“Now is the time to [get the new bivalent booster] — by Halloween, if you can,” Biden said. “That’s the best time. And that way, you can be protected for the holidays.”

COVID-19 infections and hospitalizations have risen in Europe in recent weeks. In prior surges, the Continent has often seen an uptick in COVID-19 infections before the U.S. does. 

Speaking alongside members of the White House COVID-19 Response Team, Biden said Americ…

Read more
  • 0